Image

Tim Rijkse

Associate

Tim specialises in advising on a wide range of private M&A transactions as well as transactions involving growth companies, with a key focus on the life sciences and technology sector.

He has extensive experience in working alongside both investors and founders. 

Experience

Representative matters

Dott, on its merger with TIER, forming Europe’s leading micro-mobility operator

BUX, one of Europe’s most rapidly growing neobrokers, on its acquisition by ABN AMRO

Silverflow, a payment processing technology company, on its EUR 15 million investment round led by Global Paytech Ventures

IceLake Capital on its agreement to join HeadFirst Group, a leading HR-tech service provider for professionals in the Benelux, as a new investor

ProQR Therapeutics, a Dutch biotech company that discovers and develops unique RNA therapies for severe rare and common disease, on the sale of its sepofarsen and ultevursen assets, both late-stage ophthalmic programs, to Théa

Frame Cancer Therapeutics, a growth company focused on developing cancer immunotherapies, on its EUR 32 million sale to CureVac.

Exor, a Netherlands-based diversified holding company, on their relationship agreement with Philips, a global leader in health technology, which involved the acquisition of a 15% stake in Philips by Exor, representing an investment of more than EUR 2.5 billion.

Published Work

  • T. Rijkse, ‘Ordinary course’ in tijden van corona, Ondernemingsrecht 2020/110

Qualifications

Admissions

Admitted as advocaat, Netherlands, 2019

Listed in the register of legal practice areas of the Dutch Bar Association for Company Law (Ondernemingsrecht).

Academic

LLM, Corporate law, Radboud University Nijmegen, 2018 (cum laude)
 
Grotius specialisatieopleiding Fusies en Overnames, 2023 (cum laude)

Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.